DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 065050
Email this page to a colleague
» See Plans and Pricing
NDA 065050 describes CEFOXITIN, which is a drug marketed by Acs Dobfar, Acs Dobfar Spa, Fresenius Kabi Usa, Hikma Farmaceutica, Hospira Inc, West-ward Pharms Int, B Braun, and Samson Medcl, and is included in fourteen NDAs. It is available from four suppliers. Additional details are available on the CEFOXITIN profile page.
The generic ingredient in CEFOXITIN is cefoxitin sodium. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the cefoxitin sodium profile page.
The generic ingredient in CEFOXITIN is cefoxitin sodium. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the cefoxitin sodium profile page.
Summary for 065050
| Tradename: | CEFOXITIN |
| Applicant: | West-ward Pharms Int |
| Ingredient: | cefoxitin sodium |
| Patents: | 0 |
| Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 065050
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 10GM BASE/VIAL | ||||
| Approval Date: | Sep 11, 2000 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
